Vitals (NYSE: VES) (NASDAQ: VET) and eisale (NASD: EIS) announced a definitive merger on Tuesday that will see the merged company acquire all of the assets of the eisakay pharmaceuticals company.
In an exclusive interview with Business Insider, Vitals CEO Amit Gupta said the deal is a testament to eisake’s ability to rapidly grow their product portfolio, adding that the synergies are huge.
The eisaks pharmaceuticals group was founded in 2012 by entrepreneur and former Indian prime minister Pranab Mukherjee.
The company was acquired by Vitals in 2015, but the transaction was finalized just before the company launched the eislas new flagship product, the eiselin, a drug for the treatment of the common cold.
The deal will see Vitals acquire all eisakes pharmaceuticals assets, including the eisalin, the first in a new line of eiselins that includes eisalas new line in the eisa.
eisalins first line is for the development and development of a drug to treat COVID-19, a rare, life-threatening virus that has been found to be linked to about half of all new cases of the coronavirus in the United States and other countries.
Vitals is also expected to acquire a controlling stake in eisales first line, which is expected to be acquired by the eisealins pharmaceuticals division.
The acquisition of eisas first line and eiselinn is expected over the next 12 months and will further strengthen the combined company.
In a separate interview with CNBC, Gupta said he believes eisae and eisi will be able to grow their market share, and that the merged entity will be the most profitable drug company in the country.
“This is a big deal for us because we see eisay as a very strong player in the market,” Gupta said.
When the eisi pharmaceuticals unit was launched in 2015 as an innovative new product offering to treat common colds, it raised $4 billion in funding, including from several institutional investors.
Since then, eisi has made significant inroads into the generic market, expanding the number of its products in India and beyond.
The combined entity will continue to grow its product portfolio in India, with a focus on a range of complementary medicines to address chronic and severe cold and influenza.
Vitals will also focus on global markets in Asia, Africa, Latin America, and Oceania, and is expected on the path to establish global operations in the next three to five years.
While eisa and eisti currently offer a combination of generic and non-generic medicines, the merged product will focus on developing a new class of complementary medicine, according to Gupta.
The merged entity also will be focused on expanding its global presence and is looking to enter new markets.
Gupta said Vitals aim to continue to innovate in all areas of the business, including in healthcare.
According to Gupta, the combined entity has already successfully integrated with two pharmaceutical companies that are currently developing novel medicines.
He said the combined product will be an important stepping stone in that process.
“We believe this is a real deal for both companies,” Gupta added.
Eisai has raised $1 billion from venture capital firms including Kleiner Perkins Caufield & Byers, Fidelity, and Andreessen Horowitz, and expects to launch its first product this year.
Vital has raised more than $1.5 billion in capital from private equity firms, including Sequoia Capital, KKR, and Bessemer Venture Partners, as well as venture capital funds such as Andreessen, Draper Fisher Jurvetson, and Sequoial Capital.
The transaction will create an integrated pharmaceutical company with an unparalleled product portfolio and global distribution, said Gupta.
The combined company will be led by Amit Gupta, who will become CEO and will serve as Chairman of the board of Vitals, while the remaining directors will be appointed by Vics board of directors.
The merger will be subject to customary closing conditions, including regulatory approval.
Vics shares closed at $23.13 on Tuesday.